Our bendamustine business will allow us to continue to invest in our pipeline, but the real growth going forward is, obviously, in the pipeline. We have 7 main programs to talk about today, including 4 product candidates in our late-stage pipeline. Fulvestrant as well as addition of RYANODEX indication to the nerve agent, Acute Radiation Syndrome and exertional heat stroke. These have the potential to be first or best-in-class treatments in their categories.